HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis
USA - NASDAQ:HALO - US40637H1095 - Common Stock
68.3 USD
+0.25 (+0.37%)
66.97 USD
-1.33 (-1.95%)
Taking everything into account, HALO scores 8 out of 10 in our fundamental rating. HALO was compared to 534 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making HALO a very profitable company, without any liquidiy or solvency issues. HALO is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make HALO suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year HALO was profitable.
In the past year HALO had a positive cash flow from operations.
HALO had positive earnings in each of the past 5 years.
HALO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
HALO's Return On Assets of 27.13% is amongst the best of the industry. HALO outperforms 97.94% of its industry peers.
HALO has a Return On Equity of 167.48%. This is amongst the best in the industry. HALO outperforms 99.63% of its industry peers.
Looking at the Return On Invested Capital, with a value of 28.55%, HALO belongs to the top of the industry, outperforming 98.88% of the companies in the same industry.
HALO had an Average Return On Invested Capital over the past 3 years of 17.81%. This is above the industry average of 15.38%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(28.55%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.13% | ||
| ROE | 167.48% | ||
| ROIC | 28.55% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
HALO has a better Profit Margin (47.28%) than 99.06% of its industry peers.
In the last couple of years the Profit Margin of HALO has declined.
HALO's Operating Margin of 57.92% is amongst the best of the industry. HALO outperforms 99.81% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
HALO has a better Gross Margin (84.20%) than 86.89% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 57.92% | ||
| PM (TTM) | 47.28% | ||
| GM | 84.2% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
The number of shares outstanding for HALO has been reduced compared to 1 year ago.
HALO has less shares outstanding than it did 5 years ago.
HALO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.28 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO has a better Altman-Z score (5.28) than 75.66% of its industry peers.
HALO has a debt to FCF ratio of 2.79. This is a good value and a sign of high solvency as HALO would need 2.79 years to pay back of all of its debts.
HALO's Debt to FCF ratio of 2.79 is amongst the best of the industry. HALO outperforms 93.63% of its industry peers.
HALO has a Debt/Equity ratio of 4.54. This is a high value indicating a heavy dependency on external financing.
HALO's Debt to Equity ratio of 4.54 is on the low side compared to the rest of the industry. HALO is outperformed by 82.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.54 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 5.28 |
ROIC/WACC3.64
WACC7.85%
2.3 Liquidity
A Current Ratio of 8.36 indicates that HALO has no problem at all paying its short term obligations.
HALO's Current ratio of 8.36 is fine compared to the rest of the industry. HALO outperforms 74.72% of its industry peers.
A Quick Ratio of 7.01 indicates that HALO has no problem at all paying its short term obligations.
The Quick ratio of HALO (7.01) is better than 69.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.01 |
3. Growth
3.1 Past
HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.55%, which is quite impressive.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 22.44%.
HALO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.95% yearly.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
The Earnings Per Share is expected to grow by 18.25% on average over the next years. This is quite good.
The Revenue is expected to grow by 13.85% on average over the next years. This is quite good.
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 12.13 indicates a correct valuation of HALO.
HALO's Price/Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 97.19% of the companies in the same industry.
When comparing the Price/Earnings ratio of HALO to the average of the S&P500 Index (26.13), we can say HALO is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.40, the valuation of HALO can be described as very reasonable.
97.94% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, HALO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.13 | ||
| Fwd PE | 8.4 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.07% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.78 | ||
| EV/EBITDA | 11.07 |
4.3 Compensation for Growth
HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 32.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y38.68%
EPS Next 3Y32.65%
5. Dividend
5.1 Amount
HALO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
68.3
+0.25 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.63%
Inst Owner Change-1.94%
Ins Owners0.85%
Ins Owner Change-0.2%
Market Cap7.99B
Revenue(TTM)1.02B
Net Income(TTM)557.28M
Analysts76.25
Price Target77.18 (13%)
Short Float %9.96%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.03%
Min EPS beat(2)14.79%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)16.87%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)12.25%
EPS beat(12)10
Avg EPS beat(12)12.69%
EPS beat(16)13
Avg EPS beat(16)10.59%
Revenue beat(2)2
Avg Revenue beat(2)12.25%
Min Revenue beat(2)11.69%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.78%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)5.19%
Revenue beat(12)7
Avg Revenue beat(12)3.36%
Revenue beat(16)9
Avg Revenue beat(16)2.8%
PT rev (1m)5.83%
PT rev (3m)13.57%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)10.17%
EPS NY rev (1m)-0.14%
EPS NY rev (3m)11.94%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.73%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)5.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.13 | ||
| Fwd PE | 8.4 | ||
| P/S | 6.78 | ||
| P/FCF | 14.78 | ||
| P/OCF | 14.58 | ||
| P/B | 24.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.07 |
EPS(TTM)5.63
EY8.24%
EPS(NY)8.14
Fwd EY11.91%
FCF(TTM)4.62
FCFY6.77%
OCF(TTM)4.68
OCFY6.86%
SpS10.08
BVpS2.84
TBVpS-3.85
PEG (NY)0.25
PEG (5Y)N/A
Graham Number18.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.13% | ||
| ROE | 167.48% | ||
| ROCE | 35.56% | ||
| ROIC | 28.55% | ||
| ROICexc | 39.96% | ||
| ROICexgc | 93.15% | ||
| OM | 57.92% | ||
| PM (TTM) | 47.28% | ||
| GM | 84.2% | ||
| FCFM | 45.87% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.54 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.97 | ||
| Cap/Depr | 8.67% | ||
| Cap/Sales | 0.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 71.66% | ||
| Profit Quality | 97.02% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.01 | ||
| Altman-Z | 5.28 |
F-Score8
WACC7.85%
ROIC/WACC3.64
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y48.46%
EPS Next 2Y38.68%
EPS Next 3Y32.65%
EPS Next 5Y18.25%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year31.48%
Revenue Next 2Y27.84%
Revenue Next 3Y24.03%
Revenue Next 5Y13.85%
EBIT growth 1Y68.72%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.62%
EBIT Next 3Y39.07%
EBIT Next 5Y15.57%
FCF growth 1Y84.66%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y79.07%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 8 / 10 to HALO.
What is the valuation status for HALO stock?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the valuation of HALOZYME THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HALOZYME THERAPEUTICS INC (HALO) is 12.13 and the Price/Book (PB) ratio is 24.01.
How financially healthy is HALOZYME THERAPEUTICS INC?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 8 / 10.